DOVER, N.J., March 17 /PRNewswire/ -- Germgard Lighting LLC, a New Jersey-based, early-phase medical technology company, has patented and demonstrated a revolutionary, ultra-fast, bare-hand sanitation capability. Germgard's technology will lower the cost of care and save lives by curtailing infections resulting from stays in hospitals.
Hospital Acquired Infection places great burden on patients and their families, and undermines the financial well-being of the healthcare delivery system. Indeed, in the U.S. more than 3 million patients acquire an infection during their hospital stay, with more than over $30 billion spent on various aspects of recovery. Despite this enormous expenditure, approximately 100,000 patients die annually as a result of acquiring an infection in a hospital.
According to Germgard CEO Dr. Eugene I. Gordon, "Deployment of our new, efficacious, convenient, and low-cost hand hygiene products will be the least expensive, quickest-to-implement, and most effective solution, allowing hospitals to immediately lower infection rates, reach zero tolerance targets, and properly protect patients and workers."
The ability to inactivate deadly pathogens such as MRSA and C. difficile spores and fully sanitize a nurse's or doctor's bare or gloved hands, in just one second, was absolutely unimaginable only a couple years ago. "Germgard's product is truly disruption innovation," says Cheryl Perkins, President of Innovation Edge, an industry-recognized innovation thought-leader. "Commercialization and implementation of this solution will rapidly change the infection prevention equation in healthcare facilities."
Germgard is positioned to assist hospitals run better, provide higher-quality healthcare, produce improved patient outcomes and save money. The Germgard solution will resolve the persistent issues of speed, hand irritation, and efficacy that have long plagued infection prevention
|SOURCE Germgard Lighting LLC|
Copyright©2009 PR Newswire.
All rights reserved